← Leaderboards
Natalia Higuita-Castro
Ohio State University
$1,193,629
Attributed
$2,387,257
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $528.3K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,387,257 · 2
By mechanism
R01$2,019,512 · 1
R61$367,745 · 1
Top collaborators
- Devina Purmessur (Walter)5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Devina Purmessur (walter)$1,564,971
- Benjamin A. Walter$1,594,828
- Arunark Kolipaka$3,663,630
- Jordan Taylor Moore$474,400
- Kristin I Stanford$6,188,806
Others in their field
Other Emerging Leaders on “In Situ”
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$26,358,801
- Jacob Ruff · Cornell University$22,500,000
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Elke Arenholz · Cornell University$14,750,000
- Jacob D Estes · Oregon Health & Science University$14,094,407
Research focus
In SituIn VitroFoxf1 GeneInnovationIntervertebral Disc StructureIntervertebral Disk DegenerationClinically RelevantExtracellular VesiclesGene TherapyInjuryExtracellular MatrixBiologicalEngineeringBlood VesselsBrachyury ProteinChronic Low Back PainDiscogenic PainEconomic BurdenCellsFunctional DisorderInflammationInflammatoryAnimal ModelIn Vivo
Grant awards (5)
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$481,575
R01 · FY2025 · AR
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$492,331
R01 · FY2024 · AR
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$517,259
R01 · FY2023 · AR
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$528,347
R01 · FY2022 · AR
Non-viral Reprogramming of Intervertebral Disc Cells for the treatment of Discogenic back pain$367,745
R61 · FY2019 · AR